Skip to main content

Table 1 Characteristics of participating breast cancer patients with ER+/HER2− tumors a

From: Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

Characteristics Patients, n(%) Measurement results Patients, n(%)
Age, yr   ER (Allred score b )  
  <50 250 (45%) 0 53 (9.6%)
  ≥50 305 (55%) 3 5 (0.9%)
Menopausal status   4 14 (2.5%)
  Premenopausal 300 (54%) 5 28 (5.1%)
  Postmenopausal 255 (46%) 6 66 (11.9%)
Nodal status   7 130 (23.4%)
  N1 357 (64%) 8 256 (46.1%)
  N2 151 (27%) Unknown 3 (0.5%)
  N3 47 (9%) PR (Allred score b )  
T stage   0 104 (18.7%)
  1 252 (45%) 3 10 (1.8%)
  2 276 (50%) 4 14 (2.5%)
  3 27 (5%) 5 42 (7.6%)
Grade   6 48 (8.7%)
  1 91 (16%) 7 65 (11.7%)
  2 260 (47%) 8 268 (48.3%)
  3 157 (28%) Unknown 4 (0.7%)
  Unknown 47 (9%) Ki67 (%)
Median (min-max) = 5 (0 to 80)
Treatment arm   Low (<14%) 400 (72.1%)
  FEC 280 (50.5) High (14%) 134 (24.1%)
  FEC-P 275 (49.5) Unknown 21 (3.8%)
  1. aER: Estrogen receptor; FEC: Fluorouracil, epirubicin and cyclophosphamide; FEC-P: Fluorouracil, epirubicin and cyclophosphamide followed by weekly paclitaxel; HER2: Human epidermal growth factor receptor 2; PR: Progesterone receptor. bAllred et al. [18]. Patient data were drawn from the GEICAM 9906 trial (n = 555).